CHICAGO – Blackline Review, an award-winning online news site covering Chicago’s community of notable entrepreneurs, investors and early-stage companies, has awarded AltaThera Pharmaceuticals its highest rating in six categories, in a review of the company’s business model, management team and prospects for growth.
The review – Blackline’s first evaluation of a life sciences company – includes an analysis of the company’s strategy, funding and strategic partnerships.
AltaThera, a commercial-stage pharmaceutical company focused on identifying, acquiring and developing specialty pharmaceutical products for the treatment of severe, but rare disorders, received high marks for its revenue model, product offering, value, market size and proof of concept, among other key categories.
AltaThera President and CEO Brandon Kashfian, who serves as an advisor to early-stage biotechnology and pharmaceutical companies as a founding mentor of Chicago Innovation Mentors, said the review was a reflection of the hard work AltaThera’s management team has brought to the task of growing the company while maintaining a clear focus on its mission of bringing life-saving products to underserved patient populations.
“This review is a recognition of the discipline and focus that have been key to AltaThera’s growth,” he said.
About AltaThera: AltaThera Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on critical care and alternative therapeutics for the unmet medical needs of patients with severe, and often rare, disorders for which few effective treatments are available.